Pharmaceutical - Financial, Allergan


Current filters:


Popular Filters

Allergan attacks Valeant’s financial results

Allergan attacks Valeant’s financial results


US Botox maker Allergan, the subject of a hostile $53 billion takeover attempt by Canada’s Valeant…

AllerganBusiness FinanceCanadaFinancialMergers & AcquisitionsPharmaceuticalUSAValeant PharmaceuticalsValeant Pharmaceuticals International

Allergan reports strong 2nd-qtr figures but still plan to cut 1,500 jobs worldwide

Allergan reports strong 2nd-qtr figures but still plan to cut 1,500 jobs worldwide


Botox maker Allergan has reported its second quarter operating results while also announcing that it…


Takeover target Allergen reports strong 1st-qtr sales growth


US drugmaker Allergan reported a strong set of first-quarter 2014 financial results, with global sales…

AllerganFinancialMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

Allergan adopts stockholder rights plan


USA-based Allergan, the subject of a hostile takeover bid from Canada’s Valeant Pharmaceuticals reported…

AllerganFinancialMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

Zoetis IPO caps strong month for life sciences financings, says Burrill & Co


Life sciences financing activity got a strong start in the New Year as companies raised $10.3 billion…

AllerganBiotechnologyFinancialMAP PharmaceuticalsMergers & AcquisitionsPfizerPharmaceuticalZoetis

Allergan 4th-qtr revenues up 6%; earnings exceed expectations


US health care firm Allergan (NYSE: AGN) revealed yesterday that revenues for its fiscal fourth-quarter…

AllerganFinancialMergers & AcquisitionsPharmaceutical

Allergan's1 st-qtr profits leap 45%


USA-based Allergan (NYSE: AGN) reported financial results for the first quarter of 2012, with diluted…


2011 financial briefs for Alkermes, Allergan, Gilead and Vertex


Among the plethora of financial results being reported by US biotech and pharmaceutical companies were…

AlkermesAllerganBiotechnologyFinancialGilead SciencesPharmaceuticalVertex

Back to top